Atlas Trials

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Clinical trial NCT01578707 · COMPLETED

Trial details

NCT number
NCT01578707
Sponsor
Pharmacyclics LLC.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsed or Refractory Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Start date
2012-06-01
Primary completion
2013-11-01
Enrollment
391

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.